Patents Issued in November 10, 2016
-
Publication number: 20160324910Abstract: Methods of producing a Hydrophilic Homeopathic Aqueous Substance Active (HASA)-gel matrix, include the steps of: (a) combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; (b) combining the HASA with at least one hydrophilic gelling agent; and (c) thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent or a polymerization agent.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventor: Nancy Josephine Polich
-
Publication number: 20160324911Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.Type: ApplicationFiled: May 10, 2016Publication date: November 10, 2016Inventors: Emilie Annie Claudie Fromentin, Douglas Andrew Klaiber, Daniel David Souza
-
Publication number: 20160324912Abstract: The invention provides a method of isolating one or more compounds present in fruit juice or seed extracts that have anti-microbial activity.Type: ApplicationFiled: July 15, 2016Publication date: November 10, 2016Inventors: Brant Lawrence Kedrowski, Teri Shors
-
Publication number: 20160324913Abstract: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.Type: ApplicationFiled: July 18, 2016Publication date: November 10, 2016Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan
-
Publication number: 20160324914Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.Type: ApplicationFiled: May 5, 2016Publication date: November 10, 2016Applicant: TOCOL PHARMACEUTICALS, LLCInventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen
-
Publication number: 20160324915Abstract: The present disclosure relates to a casein peptide for use in the treatment of an uterine infection in a female mammalian animal, to methods of treatment of such infections by administering to a female mammalian animal at least one casein peptide, to the use of casein peptide for the preparation of a pharmaceutical composition for treatment of uterine infection and to a kit for said treatment. The casein peptide is preferably a casein hydrolysate, e.g. obtained by trypsin hydrolysis of casein protein. The female mammalian animal is, in accordance with some embodiments, a lactating animal, the infection being a post-partum infection.Type: ApplicationFiled: November 19, 2015Publication date: November 10, 2016Applicant: Mileutis Ltd.Inventor: Jose Mario Iscovich
-
Publication number: 20160324916Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.Type: ApplicationFiled: May 13, 2016Publication date: November 10, 2016Inventor: James W. Lauderdale
-
Publication number: 20160324917Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)—based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.Type: ApplicationFiled: February 29, 2016Publication date: November 10, 2016Inventors: Jack J. Hawiger, Ruth Ann Veach, Yan Liu, Huan Qiao, Lukasz S. Wylezinski
-
Publication number: 20160324918Abstract: Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.Type: ApplicationFiled: July 21, 2016Publication date: November 10, 2016Inventors: Rutledge Ellis-Behnke, Terrence W. Norchi, Stephen Richard Kelly
-
Publication number: 20160324919Abstract: An oral modified release composition comprising cyclosporin, wherein the composition is for use in the treatment of ulcerative colitis in a patient, wherein the composition is for use in the concurrent treatment of the patient with an active agent selected from an aminosalicylate and a steroid, and a fixed or free combination thereof. Also claimed are kits comprising the oral modified release composition and the active agent. Also disclosed are methods for the treatment of ulcerative colitis using the oral modified release composition.Type: ApplicationFiled: January 12, 2015Publication date: November 10, 2016Applicant: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Publication number: 20160324920Abstract: A method of inducing cell death or apoptosis in certain (undesirable) cells, such as cancerous cells or pathogenic microorganisms. The method to be described utilizes self-replicating prion-like misfolded isoforms of a cellular protein (which may be specific to a particular type of cell) to specifically target certain undesired cells for destruction.Type: ApplicationFiled: June 24, 2016Publication date: November 10, 2016Inventor: Ian Gill Bemis
-
Publication number: 20160324921Abstract: A method of treating an eye disease comprising administering an adeno-associated virus (AAV) vector to a mammalian subject by subretinal injection, wherein the AAV vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.Type: ApplicationFiled: May 5, 2015Publication date: November 10, 2016Applicant: ISIS INNOVATION LIMITEDInventors: Robert E. MacLaren, Alun R. Barnard, Samantha R. De Silva, Mark W. Hankins
-
Publication number: 20160324922Abstract: Regulating the level of glucose in the blood of an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. Uses include managing the symptoms of hyperglycaemia and associated conditions including diabetes. The effect is both acute (post-exposure to the composition) and ongoing.Type: ApplicationFiled: August 22, 2014Publication date: November 10, 2016Inventor: Andrew John Clarke
-
Publication number: 20160324923Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.Type: ApplicationFiled: July 11, 2016Publication date: November 10, 2016Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
-
Publication number: 20160324924Abstract: Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and one or more stem cell derived factors, such as stem cell factors secreted by cultured mesenchymal stem cells (MSCs). The mammal may be a horse, dog, camel, or Homo sapiens.Type: ApplicationFiled: July 15, 2016Publication date: November 10, 2016Applicant: Riddle InstituteInventor: Michael J. Riddle, JR.
-
Publication number: 20160324925Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20160324926Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.Type: ApplicationFiled: May 16, 2016Publication date: November 10, 2016Inventors: Charles Nicolette, Stephen Brand, Zhen Zhong, Hao Wang, Jacqueline Arp, Siobhan Ramcharran, Miren Lorea Baroja
-
COMPOSITIONS AND METHODS FOR IDENTIFYING, MODULATING AND MONITORING DRUG TARGETS IN MUSCULAR DISEASE
Publication number: 20160324927Abstract: The present disclosure relates to customized therapy for disease. The present disclosure also relates to aptamer-based compositions and methods for identifying, modulating and monitoring drug targets in muscular disease (e.g., Duchenne muscular dystrophy).Type: ApplicationFiled: May 2, 2016Publication date: November 10, 2016Inventors: Larry Gold, Kirk DeLisle, David Sterling, Edward Brody, Britta Singer, Robert Mehler -
Publication number: 20160324928Abstract: The invention is directed to methods for treating blepharitis. The invention is further directed to reducing inflammation associated with blepharitis. The invention is further directed to methods for treating blepharitis and/or reducing inflammation associated with blepharitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: July 5, 2016Publication date: November 10, 2016Applicant: Noveome Biotherapeutics, Inc.Inventor: George L. Sing
-
Publication number: 20160324929Abstract: The invention relates to methods for modulating PPAR-? activity using relaxin or agonists thereof. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including small vessel disorders of the brain and those associated with increased blood-brain barrier permeability, cognitive disorders such as Alzheimer's disease, vascular dementia, epilepsy, stroke, CADASIL and migraine.Type: ApplicationFiled: July 18, 2016Publication date: November 10, 2016Applicant: The University of Vermont and State Agricultural CollegeInventor: Marilyn J. Cipolla
-
Publication number: 20160324930Abstract: Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.Type: ApplicationFiled: March 14, 2016Publication date: November 10, 2016Inventors: William P. Van Antwerp, VenKatesh R. Manda, Andrew J. L. Walsh, John Burns, Daron Evans, Hsiao Lieu
-
Publication number: 20160324931Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.Type: ApplicationFiled: May 11, 2016Publication date: November 10, 2016Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
-
Publication number: 20160324932Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.Type: ApplicationFiled: April 28, 2016Publication date: November 10, 2016Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
-
Publication number: 20160324933Abstract: A non-covalent complex of an albumin molecule and a hydrophobic ligand, compositions containing the same, and methods of use thereof are provided. The present complex may find use in delivering the hydrophobic ligand to microorganisms that have albumin-binding outer surfaces, such as a cell wall.Type: ApplicationFiled: May 6, 2016Publication date: November 10, 2016Inventors: Ravi Verma, Changjun Yu
-
Publication number: 20160324934Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: ApplicationFiled: January 30, 2015Publication date: November 10, 2016Inventors: Matthew Angel, Christopher Rohde
-
Publication number: 20160324935Abstract: A sustained-release composition for stimulating endothelial cell growth including a nitric oxide synthase within a nanoparticle comprising a biocompatible polymer is described. The sustained-release composition can be administered as part of a pharmaceutical composition, or can be coated on a medical device. The nitric oxide synthase-containing nanoparticles can be used in a method of inducing endothelium formation in a blood vessel.Type: ApplicationFiled: April 13, 2016Publication date: November 10, 2016Inventors: Vinod Labhasetwar, Jaspreet K. Vasir, Maram K. Reddy
-
Publication number: 20160324936Abstract: The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.Type: ApplicationFiled: March 23, 2016Publication date: November 10, 2016Inventors: Mark A. SUSSMAN, John A. MURASKI
-
Publication number: 20160324937Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: May 12, 2016Publication date: November 10, 2016Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20160324938Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.Type: ApplicationFiled: May 20, 2016Publication date: November 10, 2016Inventors: David Bikard, Luciano Marraffini
-
Publication number: 20160324939Abstract: The invention relates generally to methods and materials (for example animal feeds) which use dextranases for treating or controlling Campylobacter infection or colonisation, or disrupting Campylobacter biofilms. The invention has utility inter alia in eradicating or reducing the prevalence of Campylobacter in a population of animals, such as poultry.Type: ApplicationFiled: June 9, 2014Publication date: November 10, 2016Inventor: Elaine Allan
-
Publication number: 20160324940Abstract: The present invention provides, among other things, methods of treating Pompe disease, including administering to a subject in need of treatment a composition comprising an mRNA encoding acid alpha-glucosidase (GAA) at an effective dose and an administration interval such that at least one symptom or feature of Pompe disease is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.Type: ApplicationFiled: March 17, 2016Publication date: November 10, 2016Inventors: Frank DeRosa, Michael Heartlein
-
Publication number: 20160324941Abstract: Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.Type: ApplicationFiled: May 16, 2016Publication date: November 10, 2016Inventors: Michael P. Malakhov, Tiejun Li
-
Publication number: 20160324942Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: ApplicationFiled: May 5, 2016Publication date: November 10, 2016Inventors: Thomas W. Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O' Neill
-
Publication number: 20160324943Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: August 26, 2015Publication date: November 10, 2016Applicant: TEVA PHARMACEUTICALS USA, INC.Inventors: Avi TOVI, Chaim EIDELMAN, Shimon SHUSHAN, Alon HAGI, Alexander IVCHENKO, Gabriel-Marcus BUTILCA, Leah BAR-OZ, Tehila GADI, Gil ZAOVI
-
Publication number: 20160324944Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.Type: ApplicationFiled: December 29, 2014Publication date: November 10, 2016Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
-
Publication number: 20160324945Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.Type: ApplicationFiled: April 12, 2016Publication date: November 10, 2016Inventors: Dirk G. Brockstedt, Charles G. Drake, Marcella Fasso, Peter M. Lauer, William G. Hanson, Meredith Lai Ling Leong, Christopher Steven Rae
-
Publication number: 20160324946Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumour vaccine containing such a composition.Type: ApplicationFiled: May 13, 2016Publication date: November 10, 2016Inventors: Yann GODFRIN, Alice BANZ
-
Publication number: 20160324947Abstract: The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.Type: ApplicationFiled: December 2, 2014Publication date: November 10, 2016Applicant: UNIVERSITÄT ZÜRICHInventors: Arin Ghasparian, Armando Zuniga, Nina Geib, Marco Tamborini, Maja Jud, Gerd Pluschke, Aniebrys Marrero Nodarse, John Anthony Robinson
-
Publication number: 20160324948Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.Type: ApplicationFiled: January 15, 2015Publication date: November 10, 2016Inventors: JIANXIN GU, RAJESH KUMAR KAINTHAN, JIN-HWAN KIM, AVVARI KRISHNA PRASAD, YU-YING YANG
-
Publication number: 20160324949Abstract: The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.Type: ApplicationFiled: January 15, 2015Publication date: November 10, 2016Inventors: Mingming Han, Avvari Krishna Prasad, David Cooper, Wendy Jo Watson
-
Publication number: 20160324950Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.Type: ApplicationFiled: May 3, 2016Publication date: November 10, 2016Inventors: Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G.K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
-
Publication number: 20160324951Abstract: A cell, isolated nucleic acid, vector, isolated polypeptide, and method of treating a bacterial infection are provided. The cell includes a modified Acinetobacter baumannii cell having a mutation in an A. baumannii gene selected from a mutation that occurs when generating mutations in A. baumannii using transposon mutagenesis. The isolated nucleic acid includes a sequence expressing a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The vector includes the isolated nucleic acid. The isolated polypeptide includes a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The method of treating a bacterial infection includes administering to a subject an effective amount of an Acinetobacter baumannii composition including modified Acinetobacter baumannii cell.Type: ApplicationFiled: May 5, 2016Publication date: November 10, 2016Inventors: Eric P. Skaar, M. Indriati Hood, Michael Noto
-
Publication number: 20160324952Abstract: An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.Type: ApplicationFiled: January 15, 2015Publication date: November 10, 2016Applicant: SHENZHEN TAILAI BIOPHARMACEUTICALS, LLCInventors: TAO BIAN, JUAN LI, XIAO XIAO
-
Publication number: 20160324953Abstract: The present invention relates to vaccines of DNA that code for specific viral sequences. The DNA vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/YFE). Besides the wild p/YFE construct, sequence E was also fused with the sequence that codes for the human lysosome-associated membrane protein (h-LAMP), generating the construct (pL/YFE). The results of the invention are considered to be very promising, since both constructs can induce T-cell response against the same epitopes induced by the 17DD vaccine, and the pL/YFE construct can also induce a satisfactory concentration of neutralizing antibodies. The pL/YFE vector was inoculated in mice, before intracerebral challenge with the virus of yellow fever. Surprisingly, 100% of the mice immunized with pL/YFE survived the challenge.Type: ApplicationFiled: July 7, 2016Publication date: November 10, 2016Inventors: Ernesto Torres de Azevedo MARQUES, Rafael DHALIA, Romulo MACIEL FILHO
-
Publication number: 20160324954Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include nucleic acids encoding hepatitis B core antigen (HBcAg) protein in combination with one or more self-cleavage 2A polypeptides and a second antigenic polypeptide. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen. In certain embodiments the self-cleavage polypeptide is P2A. In certain embodiments the second antigenic polypeptide of interest is NS5A, HDAg, or birch allergen.Type: ApplicationFiled: May 13, 2014Publication date: November 10, 2016Inventors: Matti Sällberg, Lars Frelin, Gustaf Ahlen
-
Publication number: 20160324955Abstract: The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.Type: ApplicationFiled: June 16, 2016Publication date: November 10, 2016Applicant: DBV TECHNOLOGIESInventors: Pierre-Henri BENHAMOU, Christophe DUPONT, Lucie MONDOULET
-
Publication number: 20160324956Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Applicant: FLOW PHARMA, INC.Inventors: REID M. RUBSAMEN, DAVID EARL HECKERMAN
-
Publication number: 20160324957Abstract: Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.Type: ApplicationFiled: December 23, 2014Publication date: November 10, 2016Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: Jee LOOK, Christian Fernando RUIZ, Aaron Paul MILES, Richard William WELCH
-
Publication number: 20160324958Abstract: The present invention relates to self-assembling protein nanoparticles constructed from suitable oligomerization domains and further incorporating the TLR5 binding protein flagellin as an adjuvant molecule. Furthermore, the invention relates to the use of such nanoparticles for vaccination.Type: ApplicationFiled: January 9, 2015Publication date: November 10, 2016Applicant: ALPHA-O PEPTIDES AGInventors: Peter BURKHARD, Senthil Kumar RAMAN, Sara Maria PAULILLO, Matteo PIAZZA, Caroline KULANGARA, Christian MITTELHOLZER
-
Publication number: 20160324959Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.Type: ApplicationFiled: July 29, 2016Publication date: November 10, 2016Applicant: Valneva Austria GmbHInventors: ROBERT SCHLEGL, Michael Möhlen, Jürgen Wruss, Michael Weber